NASDAQ:GERN - Geron Stock Price, Price Target & More

Get Started

$4.07 +0.44 (+12.12 %)

(As of 05/22/2018 04:00 PM ET)

Previous Close$3.63

Today's Range$3.65 - $4.18

52-Week Range$1.74 - $6.68

Volume7.86 million shs

Average Volume5.64 million shs

Market Capitalization$610.97 million

P/E Ratio-22.61

Dividend YieldN/A

Beta2.31

About Geron (NASDAQ:GERN)

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:GERN

CUSIP37416310

Webwww.geron.com

Phone650-473-7700

Debt

Debt-to-Equity RatioN/A

Current Ratio20.80

Quick Ratio20.80

Price-To-Earnings

Trailing P/E Ratio-22.61

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million

Price / Sales658.35

Cash FlowN/A

Price / CashN/A

Book Value$0.65 per share

Price / Book6.26

Profitability

EPS (Most Recent Fiscal Year)($0.18)

Net Income$-27,910,000.00

Net Margins-3,300.12%

Return on Equity-26.20%

Return on Assets-24.58%

Miscellaneous

Employees18

Outstanding Shares173,080,000

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.32 million for the quarter. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. During the same period in the prior year, the firm posted ($0.05) EPS. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

4 Wall Street analysts have issued twelve-month price objectives for Geron's shares. Their forecasts range from $4.00 to $7.00. On average, they expect Geron's stock price to reach $5.50 in the next year. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in April. As of April 30th, there was short interest totalling 40,050,674 shares, an increase of 14.5% from the April 13th total of 34,979,045 shares. Based on an average daily trading volume, of 5,308,605 shares, the days-to-cover ratio is presently 7.5 days. Approximately 25.1% of the shares of the stock are sold short.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA) and Akcea Therapeutics (AKCA).

Who are Geron's key executives?

Geron's management team includes the folowing people:

Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel. and Portfolio & Alliance Management (Age 54)

Has Geron been receiving favorable news coverage?

News stories about GERN stock have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Geron earned a media sentiment score of 0.19 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.99 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Geron's major shareholders?

Geron's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.37%), Northern Trust Corp (1.12%), Swiss National Bank (0.18%), Arnhold LLC (0.10%), A.R.T. Advisors LLC (0.09%) and NJ State Employees Deferred Compensation Plan (0.09%). View Institutional Ownership Trends for Geron.

Which institutional investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., NJ State Employees Deferred Compensation Plan, Northern Trust Corp, MetLife Investment Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Geron.

Which institutional investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including Arnhold LLC, M Holdings Securities Inc., OMERS ADMINISTRATION Corp, UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP, Element Capital Management LLC and Swiss National Bank. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $4.07.

How big of a company is Geron?

Geron has a market capitalization of $610.97 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

MarketBeat Community Rating for Geron (GERN)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		245 (Vote Outperform)
Underperform Votes:		195 (Vote Underperform)
Total Votes:		440

MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Geron (NASDAQ:GERN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Geron in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 35.14%. The high price target for GERN is $7.00 and the low price target for GERN is $4.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.50	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.50	$5.50	$4.1667	$4.1667
Price Target Upside:	35.14% upside	29.41% upside	96.54% upside	96.54% upside

Geron (NASDAQ:GERN) Consensus Price Target History

Price Target History for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/19/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$7.00	High
3/18/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$2.50 ➝ $4.00	High
11/3/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A
7/4/2017	FBR & Co	Reiterated Rating	Buy		Medium
9/20/2016	BTIG Research	Reiterated Rating	Neutral		N/A

(Data available from 5/22/2016 forward)

Geron (NASDAQ:GERN) Earnings History and Estimates Chart

Earnings by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/8/2018
5/10/2018	Q1 18	($0.05)	($0.04)		$0.32 million	View	N/A
3/16/2018	Q4 2017	($0.04)	($0.05)	$0.41 million	$0.19 million	View	Listen
11/1/2017	Q3 2017	($0.05)	($0.04)	$0.40 million	$0.16 million	View	N/A
8/9/2017	Q2 2017	($0.05)	($0.04)	$0.38 million	$0.17 million	View	N/A
5/9/2017	Q1 2017	($0.05)	($0.05)	$0.27 million	$0.54 million	View	N/A
3/1/2017	Q416	($0.06)	($0.05)	$0.18 million	$0.09 million	View	Listen
11/3/2016	Q316	($0.06)	($0.02)	$0.22 million	$5.10 million	View	Listen
8/3/2016	Q216	($0.07)	($0.05)	$0.38 million	$0.21 million	View	Listen
5/5/2016	Q116	($0.06)	($0.06)	$0.26 million	$0.74 million	View	Listen
2/25/2016	Q415	($0.05)	($0.05)	$0.32 million	$0.22 million	View	Listen
11/5/2015	Q315	$0.11	$0.17	$17.87 million	$35.40 million	View	Listen
8/5/2015	Q2 15	($0.06)	($0.05)	$0.40 million	$0.25 million	View	N/A
4/30/2015	Q1	($0.06)	($0.06)	$0.32 million	$0.54 million	View	N/A
3/3/2015	Q4	$0.17	($0.06)	$35.35 million	$0.18 million	View	Listen
11/5/2014	Q314	($0.06)	($0.06)	$0.28 million	$0.16 million	View	N/A
8/11/2014	Q214	($0.06)	($0.06)	$0.22 million	$0.34 million	View	Listen
5/1/2014	Q114	($0.06)	($0.06)	$0.35 million	$0.47 million	View	Listen
3/27/2014		($0.06)	($0.07)			View	N/A
3/17/2014	Q413	($0.07)	($0.07)	$0.35 million	$0.23 million	View	Listen
11/7/2013	Q313	($0.06)	($0.06)	$0.49 million	$0.18 million	View	Listen
8/8/2013	Q2 2013	($0.07)	($0.07)	$0.50 million	$0.11 million	View	Listen
4/25/2013	Q1 2013	($0.08)	($0.09)	$0.71 million	$0.77 million	View	Listen
3/12/2013	Q4 2012	($0.14)	($0.12)	$0.50 million	$0.69 million	View	Listen
10/30/2012	Q312	($0.14)	($0.13)	$0.38 million	$0.6360 million	View	N/A
7/31/2012		($0.15)	($0.14)			View	N/A
5/2/2012		($0.18)	($0.15)			View	N/A
3/7/2012	Q4 2011	($0.20)	($0.22)			View	N/A
11/3/2011		($0.18)	($0.16)			View	N/A
7/28/2011		($0.18)	($0.17)			View	N/A
4/27/2011		($0.19)	($0.20)			View	N/A
2/24/2011		($0.19)	($0.39)			View	N/A
10/28/2010	Q3 2010	($0.20)	($0.19)			View	N/A
7/29/2010	Q2 2010	($0.19)	($0.18)			View	N/A
4/28/2010	Q1 2010	($0.20)	($0.18)			View	N/A
2/25/2010	Q4 2009	($0.17)	($0.20)			View	N/A
10/29/2009	Q3 2009	($0.21)	($0.17)			View	N/A
7/30/2009	Q2 2009	($0.19)	($0.23)			View	N/A
4/29/2009	Q1 2009	($0.20)	($0.20)			View	N/A
2/26/2009	Q4 2008	($0.21)	($0.22)			View	N/A
10/30/2008	Q3 2008	($0.20)	($0.22)			View	N/A
7/30/2008	Q2 2008	($0.20)	($0.17)			View	N/A
4/29/2008	Q1 2008	($0.18)	($0.18)			View	N/A
2/27/2008	Q4 2007	($0.12)	($0.22)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Geron (NASDAQ:GERN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Geron (NASDAQ GERN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 34.46%

Insider Trading History for Geron (NASDAQ:GERN)

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/29/2015	Olivia Kyusuk Bloom	CFO	Sell	2,380	$3.84	$9,139.20
3/18/2015	Thomas Hofstaetter	Director	Sell	70,000	$4.10	$287,000.00
5/29/2014	Melissa Kelly Behrs	EVP	Sell	4,826	$2.10	$10,134.60
5/29/2014	Olivia Kyusuk Bloom	CFO	Sell	3,379	$2.10	$7,095.90
5/9/2014	Daniel Bradbury	Director	Buy	142,776	$1.75	$249,858.00	142,776
4/1/2014	Melissa Kelly Behrs	EVP	Sell	12,310	$2.13	$26,220.30	147,841
4/1/2014	Olivia Kyusuk Bloom	CFO	Sell	7,435	$2.13	$15,836.55	85,347
4/1/2013	John A Scarlett	CEO	Buy	50,000	$1.03	$51,500.00

(Data available from 1/1/2013 forward)

Geron (NASDAQ GERN) News Headlines

Source:

Date	Headline
	Geron Co. (GERN) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - May 21 at 1:36 AM
	BRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBR www.reuters.com - May 18 at 6:00 PM
	Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology seekingalpha.com - May 18 at 6:00 PM
	Geron Corp (GERN) Announces Oral Presentation at EHA www.streetinsider.com - May 17 at 6:40 PM
	Implied Volatility Surging for Geron (GERN) Stock Options finance.yahoo.com - May 16 at 5:41 PM
	A Huge Decision Is on Tap for This Little Biotech Stock finance.yahoo.com - May 16 at 5:41 PM
	BidaskClub Downgrades Geron (GERN) to Sell www.americanbankingnews.com - May 16 at 11:05 AM
	Geron Annual Meeting Of Stockholders At 7:00 PM ET www.nasdaq.com - May 15 at 5:49 PM
	Is Geron (GERN) Outperforming Other Medical Stocks This Year? finance.yahoo.com - May 14 at 5:20 PM
	MARKETS: Don't buy the dip, sell the rip, warns Bank of America Merrill Lynch finance.yahoo.com - May 13 at 6:35 PM
	Geron (GERN) Rating Lowered to Hold at ValuEngine www.americanbankingnews.com - May 11 at 9:23 PM
	Geron (GERN) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS www.americanbankingnews.com - May 11 at 2:19 PM
	Geron down 8% premarket after Q1 report seekingalpha.com - May 11 at 8:28 AM
	Geron: 1Q Earnings Snapshot finance.yahoo.com - May 11 at 8:27 AM
	Geron Co. (GERN) Sees Large Growth in Short Interest www.americanbankingnews.com - May 11 at 3:06 AM
	Geron Corporation Reports First Quarter 2018 Financial Results finance.yahoo.com - May 10 at 5:56 PM
	NYSE trader: Earnings and econ data misses this week don't concern me finance.yahoo.com - May 6 at 7:41 PM
	Why Geron Corporation Stock Sank Last Month www.fool.com - May 4 at 1:17 PM
	Geron (GERN) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - May 4 at 12:54 AM
	It's Illogical To Think That Johnson & Johnson Has Dropped Geron seekingalpha.com - May 1 at 5:18 PM
	Geron Bear V. Bull - 50¢ Or $50 seekingalpha.com - May 1 at 8:26 AM
	Analysts Anticipate Geron Co. (GERN) to Post -$0.04 Earnings Per Share www.americanbankingnews.com - April 29 at 1:18 AM
	Your Daily Pharma Scoop: Geron Debates, Flexion Moves Up, Axsome Proceeds To Trial seekingalpha.com - April 27 at 8:30 AM
	Short Interest in Geron Co. (GERN) Decreases By 20.7% www.americanbankingnews.com - April 27 at 2:58 AM
	We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers seekingalpha.com - April 26 at 5:17 PM
	Geron Co. (GERN) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - April 26 at 1:42 AM
	Is Geron Corporation (GERN) Stock Outpacing Its Medical Peers This Year? finance.yahoo.com - April 25 at 5:29 PM
	Why Geron Corporation’s (NASDAQ:GERN) Ownership Structure Is Important finance.yahoo.com - April 25 at 5:29 PM
	Geron (GERN) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 24 at 12:46 PM
	Geron (GERN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 21 at 7:06 AM
	Geron (GERN) Given "Buy" Rating at FBR & Co www.americanbankingnews.com - April 19 at 10:12 PM
	Johnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug seekingalpha.com - April 19 at 5:40 PM
	Geron (GERN) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 19 at 12:49 PM
	Geron (GERN) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 18 at 12:50 PM
	Why Geron Corporation's Stock Is Heading Higher Today www.fool.com - April 18 at 8:16 AM
	Geron Faces A Make-Or-Break Catalyst This Week seekingalpha.com - April 17 at 5:54 PM
	Why Geron Corporation's Stock Is Heading Higher Today finance.yahoo.com - April 17 at 5:54 PM
	Why Geron Doesn't Pass Our Screens seekingalpha.com - April 16 at 8:16 AM
	Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report? finance.yahoo.com - April 16 at 8:16 AM
	Here's Why Geron Stock Surged More Than 90% in 6 Months finance.yahoo.com - April 13 at 5:32 PM
	Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators seekingalpha.com - April 13 at 8:19 AM
	Today’s Research Reports on Stocks to Watch: Geron Corp. and Rigel Pharmaceuticals finance.yahoo.com - April 13 at 8:19 AM
	Why Geron Corporation Stock Is on the Rise Today finance.yahoo.com - April 12 at 3:21 PM
	Geron Co. (GERN) Short Interest Update www.americanbankingnews.com - April 12 at 2:18 AM
	Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS www.americanbankingnews.com - April 12 at 1:13 AM
	BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved seekingalpha.com - April 10 at 8:27 AM
	Geron Corp.: It's Hard Enough To Get A Drug To Market Without The Questionable Bearish Arguments seekingalpha.com - April 10 at 8:27 AM
	Geron Corp.: It's Hard Enough To Get A Drug To Market Without The Misinformed Attacks seekingalpha.com - April 9 at 5:21 PM
	Geron (GERN) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 7 at 4:58 PM
	BioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help Geron seekingalpha.com - April 6 at 5:41 PM

Geron (NASDAQ:GERN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Geron (NASDAQ:GERN) Income Statement, Balance Sheet and Cash Flow Statement

Geron (NASDAQ GERN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff